Intermediate AMD Market Size in the 7MM was ~USD 990 Million in 2023 | DelveInsight

DelveInsight's " Intermediate AMD Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of intermediate AMD, historical and forecasted epidemiology as well as the intermediate AMD market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

Key Takeaways from the Intermediate AMD Market Research Report
• Among the 7MM, the US accounted for the highest prevalent cases of intermediate AMD in 2023, with around 19,861,500 cases, these cases are expected to increase during the forecast period.
• Among EU4 and the UK, the total prevalent cases of intermediate AMD were maximum in Germany, while the lowest number of cases were in Spain in 2023.
• According to the estimates, in Japan, it is observed that intermediate AMD was most prevalent in the 65-84 years age group, accounting for over 45% of total cases in 2023.
• The increase in Intermediate AMD Market Size is a direct consequence of the increasing patient population and anticipated launch of emerging therapies in the 7MM.
• As per DelveInsight analysis, the Intermediate AMD Market is anticipated to witness growth at a considerable CAGR.
• The leading Intermediate AMD Companies working in the market include Novartis, Allegro Ophthalmics, and others.
• Promising Intermediate AMD Therapies in the various stages of development include NGenuity, PAF (Positioning And Fixation device), and others.
• February 2024:- Elsan- The aim of the study will be to assess the potential functional macular effects by focal and multifocal ERG after cataract surgery with NGenuity by comparison to Standard Operating Microscope (SOM). This study would particularly address eyes at risk for macular toxicity like patients with early or intermediate AMD.

Discover which therapies are expected to grab the Intermediate AMD Market Share @ Intermediate AMD Market Outlook- https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intermediate AMD Overview
Intermediate AMD, or intermediate age-related macular degeneration, refers to a stage in the progression of age-related macular degeneration (AMD), a condition affecting the central part of the retina called the macula. In intermediate AMD, there are typically changes to the retina that may indicate a higher risk of developing advanced AMD, which can cause severe vision loss.

Intermediate AMD Epidemiology Insights
The epidemiology section of Intermediate AMD offers insights into both historical and current patient populations, as well as forecasted trends across seven major countries. This section aids in understanding the factors behind present and projected trends through analysis of various studies and input from key opinion leaders. Additionally, this portion of the market report provides information on the diagnosed patient pool, trends, and underlying assumptions.

Download the report to understand which factors are driving Intermediate AMD Epidemiology trends @ Intermediate AMD Epidemiological Insights- https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intermediate AMD Drugs Market
The Intermediate AMD Drugs Market is expected to witness substantial growth in the coming years as more targeted therapies receive regulatory approval and enter clinical practice. Additionally, ongoing research efforts aimed at better understanding the molecular mechanisms underlying Intermediate AMD signaling in Intermediate AMD are likely to uncover new therapeutic targets and further expand treatment options for patients.

Intermediate AMD Treatment Market Landscape
The Intermediate AMD treatment market landscape has witnessed significant advancements over the past years, with targeted therapies playing a crucial role in improving outcomes for patients. Among these targeted therapies, the emergence of Intermediate AMD has garnered attention in the medical community, presenting both challenges and opportunities in treatment strategies.

To learn more about Intermediate AMD treatment guidelines, visit @ Intermediate AMD Treatment Market Landscape- https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Intermediate AMD Market Outlook
The report's outlook on the Intermediate AMD market aids in developing a comprehensive understanding of historical, current, and projected trends. This is achieved by examining the influence of existing Intermediate AMD therapies, unmet needs, as well as drivers, barriers, and the demand for advanced technology. This section provides detailed insights into the trends of each marketed Intermediate AMD drug and late-stage pipeline therapy. It assesses their impact based on various factors such as annual therapy costs, inclusion/exclusion criteria, mechanism of action, compliance rates, market demand, patient population growth, covered patient segments, anticipated launch year, competition with other therapies, brand value, and input from key opinion leaders. The analyzed Intermediate AMD market data are presented concisely through relevant tables and graphs to offer a clear overview of the market dynamics.

Intermediate AMD Drugs Uptake
The drug chapter of the Intermediate AMD report provides a comprehensive analysis of both marketed drugs and late-stage pipeline drugs for this condition. It delves into the details of clinical trials, pharmacological actions, agreements, collaborations, approvals, patents, and advantages, and disadvantages of each drug, as well as the latest news and press releases related to Intermediate AMD.

Major Intermediate AMD Companies
Several Intermediate AMD Companies working in the market include Novartis, Allegro Ophthalmics, and others.

Learn more about the FDA-approved drugs for Intermediate AMD @ Drugs for Intermediate AMD Treatment- https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Intermediate AMD Market Report
• Coverage- 7MM
• Intermediate AMD Companies- Novartis, Allegro Ophthalmics, and others.
• Intermediate AMD Therapies- NGenuity, PAF (Positioning And Fixation device), and others.
• Intermediate AMD Market Dynamics: Intermediate AMD Market Drivers and Barriers
• Intermediate AMD Market Access and Reimbursement, Unmet Needs and Future Perspectives

Discover more about Intermediate AMD Drugs in development @ Intermediate AMD Clinical Trials Assessment- https://www.delveinsight.com/sample-request/intermediate-amd-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. KEY INSIGHTS
2. REPORT INTRODUCTION
3. EXECUTIVE SUMMARY OF INTERMEDIATE AMD
4. KEY EVENTS
5. EPIDEMIOLOGY AND MARKET FORECAST METHODOLOGY
6. INTERMEDIATE AMD MARKET OVERVIEW AT A GLANCE IN THE 7MM
7. DISEASE BACKGROUND AND OVERVIEW
8. EPIDEMIOLOGY AND PATIENT POPULATION
9. Patient Journey
10. Emerging Drugs
11. Intermediate AMD: Market Analysis
12. Intermediate AMD Unmet Needs
13. SWOT Analysis
14. KOL Views
15. Market Access And Reimbursement
16. Appendix
17. Delveinsight Capabilities
18. Disclaimer
19. About Delveinsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: ybhardwaj@delveinsight.com
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website:- https://www.delveinsight.com/

This release was published on openPR.